http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104109201-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 |
filingDate | 2014-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2017-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2017-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-104109201-B |
titleOfInvention | A kind of Exenatide18F labels and preparation method and application |
abstract | The invention belongs to radiopharmaceutical marker field, and in particular to a kind of 18 F‑FBEM‑Cys 39 Exenatide labels and its preparation method and application.The present invention is by by the serine (Ser of Exenatide N-terminal 39 39 ) use cysteine (Cys 39 ) be replaced, obtain new E xenatide analogs, so using analog sulfydryl and mark prothetic group ( 18 F FBEM) feature that can specifically bind, realize the telltale mark to Exenatide.Preclinical study shows, marked product 18 F‑FBEM‑Cys 39 Exenatide can be combined with the receptor-specifics of GLP 1, be the potential receptor developers of GLP 1, the diagnosis suitable for insulinoma. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113024657-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113024657-B |
priorityDate | 2014-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 146.